摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-2-(7-Amino-1,1-dioxo-1,3,4,5-tetrahydro-1λ6-benzo[f][1,2,5]thiadiazepin-2-yl)-N-benzyloxy-propionamide | 238405-99-7

中文名称
——
中文别名
——
英文名称
(R)-2-(7-Amino-1,1-dioxo-1,3,4,5-tetrahydro-1λ6-benzo[f][1,2,5]thiadiazepin-2-yl)-N-benzyloxy-propionamide
英文别名
——
(R)-2-(7-Amino-1,1-dioxo-1,3,4,5-tetrahydro-1λ6-benzo[f][1,2,5]thiadiazepin-2-yl)-N-benzyloxy-propionamide化学式
CAS
238405-99-7
化学式
C18H22N4O4S
mdl
——
分子量
390.463
InChiKey
COOGDMCNJUKVIN-CYBMUJFWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.32
  • 重原子数:
    27.0
  • 可旋转键数:
    5.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    113.76
  • 氢给体数:
    3.0
  • 氢受体数:
    6.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (R)-2-(7-Amino-1,1-dioxo-1,3,4,5-tetrahydro-1λ6-benzo[f][1,2,5]thiadiazepin-2-yl)-N-benzyloxy-propionamide 在 Pd-BaSO4 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 0.45h, 生成 N-[2-[(2R)-1-(hydroxyamino)-1-oxopropan-2-yl]-1,1-dioxo-4,5-dihydro-3H-1lambda6,2,5-benzothiadiazepin-7-yl]-3,5-dimethylbenzamide
    参考文献:
    名称:
    Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors
    摘要:
    Elevated levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with several inflammatory diseases, and therefore, strategies for its suppression have become important targets in drug discovery. Our efforts to suppress TNF-alpha have centered on the inhibition of TNF-alpha converting enzyme (TACE) through the use of hydroxamate inhibitors. Starting from broad-spectrum matrix metalloproteinase (MMP) inhibitors, we have designed and synthesized novel benzothiadiazepines as potent and selective TACE inhibitors. The benzothiadiazepines were synthesized with variation in P1 and P1' in order to effect potency and selectivity. The inhibitors were evaluated versus porcine TACE (pTACE), and the initial selectivity was assessed with counterscreens of MMP-1, -2, and -9. Several potent and selective inhibitors were discovered with compound 41 being the most active against pTACE (K-i = 5 nM) while still maintaining good selectivity versus the MMP's (at least 75-fold). Most compounds were assessed in the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA) to determine their ability to suppress TNF-alpha. Compound 32 was the most potent compound in the PBMC assay (IC50 = 0.35 muM), while compound 62 was the most active in the WBA (IC50 = 1.4 muM).
    DOI:
    10.1021/jm020475w
  • 作为产物:
    描述:
    methyl N-[(2,4-dinitrophenyl)sulfonyl]-D-alaninateN-甲基吗啉 、 lithium hydroxide 、 铁粉 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 溶剂黄146N,N-二异丙基乙胺三苯基膦偶氮二甲酸二乙酯 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 反应 32.0h, 生成 (R)-2-(7-Amino-1,1-dioxo-1,3,4,5-tetrahydro-1λ6-benzo[f][1,2,5]thiadiazepin-2-yl)-N-benzyloxy-propionamide
    参考文献:
    名称:
    Design, Synthesis, and Evaluation of Benzothiadiazepine Hydroxamates as Selective Tumor Necrosis Factor-α Converting Enzyme Inhibitors
    摘要:
    Elevated levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with several inflammatory diseases, and therefore, strategies for its suppression have become important targets in drug discovery. Our efforts to suppress TNF-alpha have centered on the inhibition of TNF-alpha converting enzyme (TACE) through the use of hydroxamate inhibitors. Starting from broad-spectrum matrix metalloproteinase (MMP) inhibitors, we have designed and synthesized novel benzothiadiazepines as potent and selective TACE inhibitors. The benzothiadiazepines were synthesized with variation in P1 and P1' in order to effect potency and selectivity. The inhibitors were evaluated versus porcine TACE (pTACE), and the initial selectivity was assessed with counterscreens of MMP-1, -2, and -9. Several potent and selective inhibitors were discovered with compound 41 being the most active against pTACE (K-i = 5 nM) while still maintaining good selectivity versus the MMP's (at least 75-fold). Most compounds were assessed in the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA) to determine their ability to suppress TNF-alpha. Compound 32 was the most potent compound in the PBMC assay (IC50 = 0.35 muM), while compound 62 was the most active in the WBA (IC50 = 1.4 muM).
    DOI:
    10.1021/jm020475w
点击查看最新优质反应信息